How RFK Jr. could restrict abortion medication access

Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. has suggested that he is open to restricting access to abortion medication, the primary method used for abortions across the U.S.

Kennedy pledged to study the abortion drug mifepristone on President Trump's request during his confirmation hearings, citing “safety issues.” He did not offer further explanation of what those issues were.

“President Trump has asked me to study the safety of mifepristone,” Kennedy said during the hearings last month. “He has not yet taken a stand on how to regulate it. Whatever he does, I will implement those policies.”

If the administration does seek to restrict access to the drug, health policy experts do not think Kennedy will attempt to remove it from the market, but say he could instead try to direct agencies within HHS to limit who can take mifepristone and how it can be administered.

“If you are trying to make a product harder to access ... you are going to institute restrictions that reduce the ease in which people can access the product,” said Caleb Alexander, a physician and professor at the Johns Hopkins Bloomberg School of Public Health with research focus on drug utilization and safety.

HHS oversees 13 agencies including the Food and Drug Administration (FDA), which is responsible for protecting public health in part by making sure that the country’s drug supplies are safe and effective for consumption.

One way the FDA tries to ensure that medications are safe is by implementing Risk Evaluation and Mitigation Strategies (REMS). These are a series of rules the agency imposes on some drugs to prevent, monitor and manage the frequency or severity of adverse health events, according to the FDA's website. They can include some interventions to ensure the safe use of medication, like an in-person dispensing requirement. Mifepristone was previously under such a requirement until the Biden administration dropped it.

Altering the REMS associated with the drug would be the most direct way to change who can take it and how, health experts said.

Though changes to REMS are often requested by the drug manufacturer, the FDA can also determine if a change is needed, according to agency guidelines. It still typically needs to work with the drug producer in those cases, however.

“The FDA may release a REMS or remove certain components of a REMS, if, after review of REMS assessments or other information, we determine that the extra measures in a REMS are no longer necessary to ensure a medication’s benefits outweigh its risks,” the agency’s website reads.

To change REMS for a drug, the FDA would need to provide evidence that itposes a danger to people and that the current REMS do not protect consumers well enough from those risks, health experts said.

The FDA first approved the abortion medication Mifeprex in 2000 and more than 100 studies conducted in at least 26 countries have found that most patients who have taken the drug have not experienced a serious complication like hospitalization or surgery.

Typically, the process for changing REMS doesn’t happen “overnight,” according to Laurie Sobel, associate director of women’s health policy at health research nonprofit KFF.

But she suggestedthe process could be different under Trump, saying the administration could potentiallyissue an emergency declaration based on a study arguing that mifepristone is dangerous and revert back to earlier REMS for the drug.

Such a move could eventually make it harder to access to drug by reinstituting rules thatallowed only certain clinicians the right to prescribe it, she said.

Since 2000, the abortion medication has had a series of REMS that have been modified. The Biden-era FDA's announcement in 2021 that it woulddrop its requirement that the drug be dispensed in person to patients marked one of the more recent modifications.

That requirement was officially dropped in 2023, with the agency releasing new REMS for the drug.

In addition to seeking to roll back that change, the Trump FDA could also possibly suggest placing new requirements in the REMS that patients seeking mifepristone must undergo specific tests before they can be given the drug or be observed for a certain amount of time in clinic after it, according to Alexander.

If the agency were to suggest changes to REMS for mifepristone, the drug’s manufacturers Danko Laboratories and GenBioPro, which creates a generic version of the drug, would likely challenge the changes in court, health experts said.

“But it’s unclear how successful that challenge might be,” said Sobel.

The FDA did not answer questions from The Hill about REMS for mifepristone.

Topics

Healthy Returns: HHS Secretary RFK Jr. is making early moves that may affect vaccine access

Robert F. Kennedy Jr. is making moves that could affect immunization uptake and policy in the U.S., while Oracle submits a formal application to join TEFCA.
CNBC - 1d
How Medicaid cuts could improve access to care

Coverage — having health insurance — most certainly does not guarantee timely medical care.
The Hill - 1h
AP sues over White House access restrictions

The Associated Press sued White House officials Friday for restricting the wire service’s access to the Oval Office and Air Force One over its refusal to use “Gulf of America” in its AP Stylebook. ...
The Hill - 5d
RFK Jr. Announces New HHS Guidance Recognizing Only Two Sexes

The new guidance follows President Trump’s demand that the Health and Human Services Department align with his executive order barring transgender athletes from women’s sports.
The New York Times - Feb. 19
Top FDA official resigns, warns firings will backfire on RFK Jr.

James Jones resigned as FDA deputy commissioner and said the Trump administration's "indiscriminate" job cuts show "disdain for the very people necessary to implement your agenda."
CBS News - 6d
RFK Jr. thrusts antidepressants into the spotlight — unnecessarily, advocates say

RFK Jr. plans to investigate SSRI and antidepressant use, particularly among children and teens, as part of the “Make America Healthy Again” movement.
NBC News - 6d
With RFK Jr. in charge, supplement makers see chance to cash in

The FDA is already limited in policing claims of health benefits by makers of supplements and herbal remedies — a $70 billion industry. Get ready for even less regulation.
CBS News - 6d
RFK Jr. targets childhood psychiatric drugs; doctors push back

Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. has made psychiatric medications a focus of his review of the country’s childhood chronic disease crisis, claiming they’ve been ...
The Hill - 1d
'It's not unusual': RFK Jr. comments on growing Texas measles outbreak

When questioned about a growing measles outbreak in West Texas that has claimed at least one life, Health & Human Services Secretary Robert F. Kennedy Jr. told reporters "we have measles outbreaks ...
NBC News - 21h